Ocrelizumab for treatment of multiple sclerosis

3Citations
Citations of this article
50Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Ocrelizumab is a monoclonal antibody directed against the differentiation antigen CD20, which leads to an effective long-term depletion of lymphocytes, in particular B cells. Recently published phase 3 studies confirmed that ocrelizumab is effective in the treatment of both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Based on these results, ocrelizumab was the first drug to be approved for primary chronic progressive MS. To place this therapeutic breakthrough in the context of the current MS therapeutic landscape, it is worthwhile taking a look back at the development of antibody-mediated CD20 depletion, the studies underlying the approval of ocrelizumab and their open extension phases. This review article discusses the available data on the efficacy and safety of long-term B‑cell depletion in MS patients and reviews current knowledge on the role of B‑lymphocytes in the immunopathogenesis of MS.

Cite

CITATION STYLE

APA

Graf, J., Albrecht, P., Goebels, N., Aktas, O., & Hartung, H. P. (2020, August 1). Ocrelizumab for treatment of multiple sclerosis. Nervenarzt. Springer Medizin. https://doi.org/10.1007/s00115-020-00937-6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free